Latest / WTR Small-Cap Spotlight
Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments
Send us Fan Mail
In our latest WTR Small-Cap Spotlight x Healthcare Crossover, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that highlight advantages that distinguish Cybin's lead program CYB003 from other aspiring late-stage novel therapies in the depression treatment landscape
Cybin (NYSE: CYBN) is a late-stage clinical development company focused on developing novel psychedelic-based…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.